Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pomalidomide in Systemic Sclerosis with Interstitial Lung Disease
NCT01559129Phase 2Terminated
- Sponsor
- Celgene Corporation
- Start
- Aug 2012
- Primary completion
- Nov 2016
- Modality
- Molecular Glues
- Countries
- 10
01
Overview
A Phase 2 trial of pomalidomide in systemic sclerosis (SSc), interstitial lung disease (ILD), sponsored by Celgene Corporation. Started Aug 2012; status: terminated.
02
Drugs
pomalidomide
03
Conditions
systemic sclerosis (SSc)interstitial lung disease (ILD)
Beyond the preview
Go deeper on NCT01559129.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01559129.